Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Simcere Pharmaceutical Group Limited ( (HK:2096) ) has shared an announcement.
Simcere Pharmaceutical Group expects its 2025 revenue to rise about 16%–17.6% year on year to roughly RMB7.7 billion–RMB7.8 billion, underscoring solid top-line momentum from its core pharmaceutical operations. The company has restated 2024 figures to reflect the acquisition of Xianwei (Hainan) Biotechnology, incorporating the business as if owned for the full comparative period.
Management projects 2025 profit attributable to shareholders of RMB1.3 billion–RMB1.4 billion, an increase of about 80%–94% over the restated 2024 profit, with adjusted profit up roughly 24%–34%. The earnings improvement is mainly attributed to growth in innovative drug revenue, out-licensing income and net fair-value gains on investments, though the figures remain unaudited and subject to adjustment, prompting a cautionary stance for investors until full results are released in March 2026.
The most recent analyst rating on (HK:2096) stock is a Buy with a HK$16.30 price target. To see the full list of analyst forecasts on Simcere Pharmaceutical Group Limited stock, see the HK:2096 Stock Forecast page.
More about Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited is a Hong Kong–incorporated drugmaker focused on innovative pharmaceuticals, with revenue driven by its innovative drug business and related licensing activities. The group also maintains an investment portfolio whose fair value movements can materially influence its reported profitability and adjusted performance metrics.
Average Trading Volume: 6,798,427
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$33.69B
For a thorough assessment of 2096 stock, go to TipRanks’ Stock Analysis page.